Maze Therapeutics (MAZE) Change in Accured Expenses (2024 - 2026)

Maze Therapeutics (MAZE) has 3 years of Change in Accured Expenses data on file, last reported at -$4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 282.5% year-over-year to -$4.1 million; the trailing twelve-month figure through Mar 2026 stood at $479000.0 (down 83.34% YoY), and the FY2025 full-year result was $3.5 million, down 8.54% from the prior year.
• Change in Accured Expenses slipped to -$4.1 million in Q1 2026, from $2.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.8 million in Q2 2024 to a low of -$4.1 million in Q1 2026.
• A 3-year average of $358111.1 and a median of $106000.0 in 2025 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 245.31% in 2025, while the deepest fall reached 711.45% in 2025.
• Tracing MAZE's Change in Accured Expenses over 3 years: stood at $1.8 million in 2024, then grew by 6.51% to $2.0 million in 2025, then plunged by 307.13% to -$4.1 million in 2026.
• Business Quant data shows MAZE's Change in Accured Expenses at -$4.1 million in Q1 2026, $2.0 million in Q4 2025, and $2.5 million in Q3 2025.